- $31.89bn
- $33.90bn
- $9.89bn
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
Brief: Biogen To Pause Or Terminate Investment In Majority Of Legacy Apellis Research Programs, Says Spokesperson
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Biogen targets immunology growth with $1 billion RayThera deal (updated)
Biogen to acquire RayThera for $1 billion
Brief: Biogen Expands Immunology Pipeline With Agreement To Acquire Raythera Inc.
Brief: Biogen Canada Disappointed By Outcome Of Pan-Canadian Pharmaceutical Alliance Negotiations For Skyclarys
Factbox: Global drugmakers invest billions to boost US presence
Biogen to pay $18.9 million to settle investors' claims over Alzheimer's drug
U.S. STOCKS ON THE MOVE -Honeywell, Broadcom, Carlyle
U.S. STOCKS ON THE MOVE-UnitedHealth, Pinterest, Celcuity
Biogen up after FDA grants 'breakthrough' tag for neuromuscular disorder drug
Brief: UCB And Biogen Announce Positive DZP Phase 3 Study Results
Italy probes Biogen for allegedly hindering sales of rival's MS drug (updated)
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position